{
    "clinical_study": {
        "@rank": "41761", 
        "arm_group": [
            {
                "arm_group_label": "ALD403", 
                "arm_group_type": "Experimental", 
                "description": "Single IV Dose on Day 0"
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single IV infusion on Day 0"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single\n      dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for\n      24 weeks."
        }, 
        "brief_title": "Safety, Efficacy and Pharmacokinetics of ALD403", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Diagnosis of migraine at \u2264 50 years of age (ICHD-II, 2004 Section 1)\n\n          -  History of migraine \u2265 12 months with\n\n               -  \u2265 5 and \u2264 14 migraine days in each 28 day period in the 3 months prior to\n                  screening\n\n               -  use of acute migraine medications \u2264 14 days per 28 day period and, within those\n                  days, \u2264 10 days of triptan use per 28 day period in the 3 months prior to\n                  screening and the 28 day period of completion of eDiary prior to randomization\n\n          -  Women of child-bearing potential and males with partners of child-bearing potential\n             must agree to use adequate contraception (oral or injectable [depot] estrogen, and/or\n             progestogen, or selective estrogen receptor modulator contraceptive therapeutic,\n             intrauterine contraceptive device, or double barrier method [e.g., condom and\n             diaphragm or spermicidal gel]). Non-childbearing potential is defined as\n             post-menopausal for at least 1 year or surgical sterilization or hysterectomy at\n             least 3 months before screening\n\n          -  Any hormonal therapy (e.g., oral contraceptives, hormone replacement therapy) use is\n             stable and ongoing for at least 3 months prior to screening and during the 28 day\n             period from screening to randomization\n\n          -  Agree not to post any personal medical data related to the trial or information\n             related to the trial on any website or social media site (e.g., Facebook, Twitter)\n             until the trial has been completed\n\n        Exclusion Criteria\n\n          -  Confounding pain syndromes including fibromyalgia, chronic musculoskeletal (e.g., low\n             back pain), psychiatric conditions, dementia, or major neurological disorders other\n             than migraine that interfere with the participation in the trial\n\n          -  Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache,\n             hemicrania continua, new daily persistent headache, basilar, hemiplegic, or familial\n             hemiplegic migraine\n\n          -  Regular use (greater than 7 days) of prophylactic headache medication (any preventive\n             medication or supplement with evidence of efficacy from at least 1 placebo-controlled\n             trial) within 3 months, or onabotulinumtoxin A within 6 months prior to screening or\n             during the 28 day period prior to randomization\n\n          -  Cardiac surgery or cardiac symptoms within 3 months of screening and during the 28\n             day period prior to randomization\n\n          -  Suspected or diagnosis of hypertension with or without antihypertensive treatment\n\n          -  Any ongoing co-morbidity that in the opinion of the Investigator will interfere with\n             the participation in the trial\n\n          -  Body Mass Index (BMI) > 39 at screening\n\n          -  Pregnant, breast-feeding, or planning to become pregnant during the trial\n\n          -  Patients who have used opioids > 5 days for the treatment of pain in more than 2 of\n             the 6 months prior to screening or in the 28 day period prior to randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "163", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772524", 
            "org_study_id": "ALD403-CLIN-002"
        }, 
        "intervention": {
            "arm_group_label": "ALD403", 
            "intervention_name": "ALD403", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Migraine Disorders", 
            "Phase 1", 
            "ALD403"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85027"
                    }, 
                    "name": "Premiere Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "ACT Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Collaborative Neuroscience Network, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92108"
                    }, 
                    "name": "Medical Center for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "San Francisco Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "CA Medical Clinic for Headache"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94598"
                    }, 
                    "name": "Diablo Clinical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hallandale Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33009"
                    }, 
                    "name": "MD Clinical"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33161"
                    }, 
                    "name": "Segal Institute for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33409"
                    }, 
                    "name": "Palm Beach Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roslindale", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02131"
                    }, 
                    "name": "Boston Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Watertown", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02472"
                    }, 
                    "name": "MedVadis Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48104"
                    }, 
                    "name": "Michigan Headache & Neurological Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65807"
                    }, 
                    "name": "Clinvest"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11235"
                    }, 
                    "name": "SPRI"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14609"
                    }, 
                    "name": "Rochester Clinical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Wake Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45255"
                    }, 
                    "name": "Community Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mt. Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "Coastal Carolina Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37421"
                    }, 
                    "name": "ClinSearch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76017"
                    }, 
                    "name": "Neurology Associates of Arlington"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Premiere Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }, 
                    "name": "CRI Lifetree"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Virginia Beach", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23454"
                    }, 
                    "name": "Tidewater Integrated Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Seattle Women's: Health, Research, Gynecology"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines", 
        "overall_official": {
            "affiliation": "Alder Biopharmaceuticals", 
            "last_name": "Jeff Smith, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Physical Examination\nVital signs\n12-lead ECG (electrocardiogram)\nClinical laboratory tests (hematology, chemistry)\nNumber of participants with Adverse Events", 
            "measure": "Safety of ALD403: laboratory variables, ECG and adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax - maximum plasma concentration\nTmax - Time to achieve maximum plasma concentration\nAUC - Area under the plasma concentration-time curve\nT1/2 - Elimination half-life\nVz - Volume of distribution\nCL - Clearance\nBioavailability\nPlasma levels of unbound ALD403", 
                "measure": "Evaluation of Pharmacokinetics of ALD403", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Change in frequency of migraine days compared to baseline\nResponder rate\nMigraine hours\nMigraine episodes\nMigraine severity\nUse of acute migraine medications", 
                "measure": "Efficacy of ALD403", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Alder Biopharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alder Biopharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}